The Semax variants are a small family built on one shared heptapeptide backbone, and across the published record they differ far less in what they do than in how long they survive before enzymes clip them. The base peptide, the N-acetylated form, and the C-terminal amidated form each cap a different vulnerable end of the same active fragment, so comparisons rest on degradation resistance, effective dose, onset and duration, and route rather than on separate mechanisms. Much of the comparative data comes from preclinical work and manufacturer characterization rather than large human trials, and none of these variants holds broad pharmaceutical approval in most jurisdictions.
The Semax variants share one identical active heptapeptide, so documented differences center on degradation resistance and duration rather than distinct mechanisms, and most carry no marketing approval outside a limited set of countries.
The base Semax molecule is a heptapeptide, Met-Glu-His-Phe-Pro-Gly-Pro, whose first four residues reproduce a biologically active fragment of adrenocorticotropic hormone while the trailing proline-glycine-proline tail is an engineered addition, not a natural continuation of the hormone. That tail is the original design's defining trick: free ACTH fragments are degraded almost immediately by peptidases, so the proline-rich terminus slows enzymatic clipping enough for the active fragment to persist. Membership in the family is defined by keeping this backbone intact, with every recognized variant differing only in the capping groups attached to its ends.
Every recognized Semax variant retains the identical Met-Glu-His-Phe-Pro-Gly-Pro heptapeptide backbone, and the differences between variants come entirely from capping groups added to the chain's ends rather than from any change to the core sequence.
N-acetylation attaches an acetyl group to the free amino terminus, converting a reactive, charged end into a neutral, capped one. The documented consequence targets aminopeptidases, the enzymes that degrade peptides from the amino end inward; with that entry point masked, degradation slows and the acetylated form is characterized as holding a longer functional half-life than the unmodified peptide. The cap is described as protective rather than activating, so reported activity is similar in kind to the base peptide, with durability standing as the main reported advantage.
N-acetylation caps the amino terminus to block aminopeptidase degradation, and the acetylated form is characterized in preclinical and manufacturer data as retaining a longer functional half-life than unmodified Semax while keeping the same class of activity.
Where N-acetylation shields the front of the molecule, amidation replaces the free carboxylic acid at the tail with a carboxamide group, swapping a negatively charged terminus for a neutral one. The immediate documented benefit is protection against carboxypeptidases, which degrade peptides from the carboxyl end, so an amidated variant defends a different flank than an acetylated one. In many bioactive peptides a C-terminal amide is also required for proper receptor recognition, though for the Semax family, whose active fragment sits toward the N-terminal side, amidation is generally framed as a stability enhancement rather than a change that unlocks new signaling.
| Property | N-acetylation | Amidation |
|---|---|---|
| Terminus protected | Amino (N-terminus) | Carboxyl (C-terminus) |
| Enzyme blocked | Aminopeptidases | Carboxypeptidases |
| Charge change | Removes N-terminal positive charge | Removes C-terminal negative charge |
| Primary documented role | Stability, longer half-life | Stability, with a possible receptor-recognition role |
Amidation caps the carboxyl terminus against carboxypeptidases, protecting the opposite end from N-acetylation, and for the Semax family it is documented as a stability enhancement rather than a change that unlocks new receptor signaling.
Duration differences among the variants trace almost entirely to which enzymatic entry points each cap closes. The unmodified base peptide is vulnerable at both ends despite the proline-rich tail already blunting much of the attack, N-acetylation shuts the aminopeptidase route, and amidation shuts the carboxypeptidase route at the far end, so a doubly modified molecule would in principle resist a broader spectrum of clipping. The published caveat is that a longer bench half-life, usually measured by incubation in plasma or tissue homogenate, does not map one-to-one onto a proportionally longer effect.
Bench half-life measured in plasma or tissue homogenate gives a directional durability ranking in which capping more termini extends survival, but a longer biochemical half-life does not translate into a proportionally longer effect because receptor occupancy, distribution, and downstream signaling intervene.
Because every variant carries the identical active heptapeptide, intrinsic potency is expected to differ only modestly, and most reported divergence is really a downstream consequence of stability rather than a true difference at the target. A longer-surviving variant delivers more sustained exposure from the same nominal dose, which can read as greater apparent potency even when activity at the receptor is unchanged. The attributed effects, described in neuropeptide terms such as attention, cognitive endurance, and neuroprotective signaling, are reported in similar terms across the variants.
Confident rankings of one Semax variant as more potent than another outrun the available data, since the shared backbone makes intrinsic potency differences modest and most apparent divergence reflects longer exposure from a more stable molecule rather than a true difference at the target.
Route matters as much as intrinsic stability because these peptides face aggressive degradation at nearly every absorption surface, and the family is most often associated with intranasal delivery, which reaches systemic and central compartments while bypassing the first-pass environment of the gut and liver. Oral routes are punishing for short peptides: stomach acid and gut proteases degrade them heavily and the intestinal wall passes very little intact peptide, so oral bioavailability is characterized as poor across the whole family. A more degradation-resistant variant survives longer at the mucosal surface, so the same caps that extend plasma half-life tend to modestly improve the fraction of an applied dose that arrives intact, though the differences are relative rather than transformative.
| Criterion | Intranasal | Oral |
|---|---|---|
| Proteolytic exposure | Lower; bypasses gut and liver first-pass | High; acid and gut proteases degrade heavily |
| Documented bioavailability | The family's most-associated route | Poor for short peptides across the family |
| Effect of terminal caps | More stable variants lose less at the mucosa | Little intact peptide passes regardless of cap |
All Semax variants are documented as suited to routes that minimize proteolytic exposure, with intranasal delivery the family's most-associated route and oral bioavailability poor across the board, while more degradation-resistant variants lose modestly less of an applied dose.
Regulatory status is one of the sharpest genuine differences within the family, and it turns on jurisdiction and approval history rather than chemistry. The base peptide has an approval and clinical-use history in a limited number of countries where it is handled as a registered medicine, while in most other jurisdictions neither it nor its modified relatives holds marketing approval, leaving them to circulate through research-chemical and specialty-compounding channels. A chemically modified variant does not inherit the base peptide's status: a new terminal cap can make the molecule a legally distinct, never-authorized substance, which frequently leaves the acetylated and amidated forms in a Research Use Only posture, labeled not for human consumption.
A chemically modified Semax variant does not automatically inherit the base peptide's approved status; a new terminal cap can make it a legally distinct, unevaluated substance, which frequently leaves the acetylated and amidated forms in a Research Use Only posture even where the parent holds approval in some countries.
Cost and availability differences across the family flow mostly from synthesis complexity and market demand rather than from any large gap in raw materials. Every variant starts from the same heptapeptide, but each terminal modification adds a synthesis and purification step, so acetylated or amidated forms generally carry a price premium over the plain peptide and a doubly modified molecule costs more still. Because most of this trade happens in a research-grade rather than pharmaceutical channel, sourcing carries real consistency risk in purity and actual peptide content, which makes independent verification through a certificate of analysis or third-party testing a genuine and often underappreciated part of the true cost.
Each terminal modification adds a synthesis and purification step, so acetylated and amidated forms carry a price premium over the base peptide and a doubly modified molecule costs more still, while research-grade sourcing makes certificate-of-analysis or third-party purity verification a real component of the true cost.
Educational use only. This article describes what the published scientific and clinical literature reports about Semax and its variants (N-Acetyl Semax and N-Acetyl Semax Amidate). It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
